All issues

FDA calendar and trial changes: week to 19 November 2026

Week to 19 Nov 2026: 5 FDA calendar events in the next 60 days, 19 clinical trial record changes on ClinicalTrials.gov. Every item links to its source.

On the FDA calendar, next 60 days

Date as reportedDrug / companyEventEvidence
30 Nov 2026bezuclastinibCogent Biosciences, Inc. (COGT)PDUFA dateGISTOpen original source
22 Dec 2026LorundrostatMineralys Therapeutics Inc. (MLYS)PDUFA datehypertension in combination with other antihypertensive drugsOpen original source
22 Dec 2026LorundrostatMineralys Therapeutics Inc. (MLYS)PDUFA datetreatment of hypertension in combination with other antihypertensive drugsOpen original source
30 Dec 2026bezuclastinibCogent Biosciences, Inc. (COGT)PDUFA dateNonAdvSMOpen original source
30 Dec 2026bezuclastinibCogent Biosciences, Inc. (COGT)PDUFA dateNonAdvSMOpen original source

Open the full FDA calendar

Trial record changes this week

· 5 fields changed

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Primary completion date changed

Before: Oct 2026. After: 28 Oct 2026.

Participant count changed

Before: 450 participants (planned). After: 357 participants (actual).

Participant count type changed

Before: Estimated. After: Actual.

Completion date type changed

Before: Estimated. After: Actual.

Check registry source

· 5 fields changed

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Primary completion date changed

Before: Dec 2026. After: 2 Jun 2026.

Participant count changed

Before: 244 participants (planned). After: 279 participants (actual).

Participant count type changed

Before: Estimated. After: Actual.

Completion date type changed

Before: Estimated. After: Actual.

Check registry source
NAI for Sepsis With Persistent Lymphopenia

NCT07578558 · ImmunityBio, Inc. (IBRX)

· 3 fields changed

Recruitment status changed

Before: Not yet recruiting. After: Withdrawn.

Participant count changed

Before: 50 participants (planned). After: 0 participants (actual).

Participant count type changed

Before: Estimated. After: Actual.

Check registry source
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359 · ADARx Pharmaceuticals, Inc. (ADRX)

· 3 fields changed

Primary completion date changed

Before: 31 Dec 2028. After: 30 Apr 2030.

Planned enrollment increased by 40 participants

Before: 45 participants (planned). After: 85 participants (planned).

Main study measure wording changed

Compare the two versions on the trial page.

Check registry source

· 3 fields changed

Primary completion date changed

Before: Mar 2027. After: 21 Oct 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Completion date type changed

Before: Estimated. After: Actual.

Check registry source
Monthly Dosing of Atacicept in IgAN

NCT07020923 · Vera Therapeutics, Inc. (VERA)

· 2 fields changed

Primary completion date changed

Before: Sep 2026. After: 22 Sep 2026.

Completion date type changed

Before: Estimated. After: Actual.

Check registry source

Showing 12 of 19 recorded updates. Search all tracked trials · Read the latest monthly report